Compare AbbVie Inc (ABBV) vs Danaos Corporation (DAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Danaos Corporation — how do they compare? AbbVie Inc trades at $253.8 (market cap $449.91B), while Danaos Corporation trades at $127.14 (market cap $2.27B). The key difference: AbbVie Inc is far larger — about 198.2× Danaos Corporation's market cap, and Danaos Corporation pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| ABBV | DAC | |
|---|---|---|
Market Cap | $449.91B | $2.27B |
Sector | Health | Technology |
52-Week High | $261.07 | $134.63 |
52-Week Low | $184.85 | $84.05 |
Enterprise Value | $513.38B | $2.28B |
Dividend Yield | 2.72% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Danaos Corporation (DAC) trades at $125.34, up 2.47% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 4.42 and net income margin near 50%, supported by consistent dividend payments. Recent earnings beat expectations in two of the last three quarters, with Q2 2026 results pending.
Outlook remains positive due to deep value metrics and robust cash flow, but risks include cyclical shipping demand and capital expenditure pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid solid operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →
